Search Result

Results for "

P-110

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (9) Autophagy (12) Casein Kinase (2) DNA-PK (8) Dynamin (3) Influenza Virus (1) mTOR (7) PI3K (46) PIKfyve (1)
By Research Areas:	Cancer (42) Cardiovascular Disease (4) Infection (2) Inflammation/Immunology (6) Metabolic Disease (2) Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P2280

TAT-P110 P110	Dynamin	Neurological Disease Inflammation/Immunology
TAT-P110, a peptide inhibitor of Drp1-Fis1 interaction, reduces pathology in numerous models of neurodegeneration, ischemia, and sepsis without blocking the physiological functions of Drp1 .

HY-P10368

P110 heptapeptide	Dynamin	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
P110 heptapeptide, a peptide inhibitor of Drp1-Fis1 interaction, reduces pathology in numerous models of neurodegeneration, ischemia, and sepsis without blocking the physiological functions of Drp1 .

HY-114428

P110δ-IN-1	PI3K	Cancer
P110δ-IN-1 is a potent and selective inhibitor of *P110δ* extracted from patent WO 2014055647 A1, with an IC₅₀ of 8.4 nM .

HY-15180

Buparlisib Hydrochloride 70+ Cited Publications BKM120 Hydrochloride; NVP-BKM120 Hydrochloride	PI3K Apoptosis	Cancer
Buparlisib Hydrochloride (BKM120 Hydrochloride) is a pan-class I PI3K inhibitor, with IC₅₀ of 52 nM/166 nM/116 nM/262 nM for *p110α/p110β/p110δ/p110γ*, respectively.

HY-17044

Duvelisib 5+ Cited Publications IPI-145; INK1197	PI3K	Cancer
Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC₅₀ of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively .

HY-111184

PIK-108	PI3K	Cancer
PIK-108 is a non-ATP competitive, allosteric *p110β/p110δ* selective inhibitor .

HY-70063

Buparlisib 70+ Cited Publications BKM120; NVP-BKM120	PI3K Apoptosis	Cancer
Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC₅₀s of 52, 166, 116 and 262 nM for *p110α, p110β, p110δ* and *p110γ*, respectively.

HY-13281

PIK-75 hydrochloride 4 Publications Verification	DNA-PK PI3K Apoptosis	Cancer
PIK-75 hydrochloride is a reversible DNA-PK and *p110α*-selective inhibitor, which inhibits DNA-PK, *p110α* and p110γ with IC₅₀s of 2, 5.8 and 76 nM, respectively. PIK-75 hydrochloride inhibits p110α >200-fold more potently than p110β (IC₅₀=1.3 μM) . PIK-75 hydrochloride induces apoptosis .

HY-107834

PIK-75 4 Publications Verification	DNA-PK PI3K Apoptosis	Cancer
PIK-75 is a reversible DNA-PK and *p110α*-selective inhibitor, which inhibits DNA-PK, p110α and p110γ with IC₅₀s of 2, 5.8 and 76 nM, respectively. PIK-75 inhibits p110α >200-fold more potently than p110β (IC₅₀=1.3 μM) . PIK-75 induces apoptosis .

HY-P6437

Drp1 peptide inhibitor P110	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-13504

PIK-293 1 Publications Verification	PI3K	Metabolic Disease Cancer
PIK-293, an analog of IC87114, is a PI3K inhibitor, with IC₅₀ values of 0.24 μM, 10 μM, 25 μM and 100 μM for p110δ, p110β, p110γ and p110α, respectively .

HY-12235

PI-3065 3 Publications Verification	PI3K	Inflammation/Immunology Cancer
PI-3065 is a potent inhibitor of PI3K p110δ, with IC₅₀ and K_i values of 5 nM and 1.5 nM, and exhibits less potent activity against p110α, p110β, p110γ with IC₅₀s of 910, 600, >10000 nM.

HY-10303

PIK-294 2 Publications Verification	PI3K	Cancer
PIK-294 is a potent *p110δ*-selective inhibitor with an IC₅₀ of 10 nM.

HY-15244A

Alpelisib hydrochloride BYL-719 hydrochloride	PI3K	Cancer
Alpelisib hydrochloride (BYL-719 hydrochloride) is a potent, orally active, and selective PI3Kα inhibitor with IC₅₀s of 5 nM, 250 nM, 290 nM and 1200 nM for *p110α, p110γ, p110δ, and p110β*, respectively. Alpelisib hydrochloride (BYL-719 hydrochloride) shows antineoplastic activity .

HY-50673

Dactolisib 55+ Cited Publications BEZ235; NVP-BEZ235	PI3K mTOR Autophagy	Cancer
Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and mTOR kinase inhibitor with IC₅₀s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for *p110α/p110γ/p110δ/p110β* and mTOR, respectively. Dactolisib (BEZ235) inhibits both mTORC1 and mTORC2.

HY-15244

Alpelisib 90+ Cited Publications BYL-719	PI3K	Cancer
Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC₅₀s of 5/250/290/1200 nM, respectively. Antineoplastic activity .

HY-100706

AMA-37	DNA-PK	Cancer
AMA-37, an Arylmorpholine analog, is ATP-competitive DNA-PK inhibitor, with IC₅₀ values of 0.27 μM (DNA-PK), 32 μM (p110α), 3.7 μM (p110β), and 22 μM (p110γ), respectively .

HY-15245

GSK2636771 5+ Cited Publications	PI3K	Cancer
GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3Kβ with a K_i of 0.89 nM and an IC₅₀ of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms.

HY-10115

PI-103 20+ Cited Publications	PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 is a potent PI3K and mTOR inhibitor with IC₅₀s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for *p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK* with an IC50 of 2 nM. PI-103 induces autophagy .

HY-10115A

PI-103 Hydrochloride 20+ Cited Publications	PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC₅₀s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for *p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK* with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy .

HY-157287

(S)-Phe-A110/B319	Others	Inflammation/Immunology
(S)-Phe-A110/B319 is a selective binde that has 20-fold higher affinity towards the H1047R mutant of p110α in the p110α/p85α PI3K complex .

HY-124535

TGX-115	PI3K	Cardiovascular Disease
TGX-115 is a cytopermeable and potent PI3-K isomer p110β/p110δ inhibitor (p110β IC₅₀ value of 0.13 μM, p110δ IC₅₀ value of 0.63 μM).TGX-115 is an enzyme that regulates platelet adhesion process and inhibits phosphoinosine 3-kinase. TGX-115 can be used in the study of cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, restenosis, arteriosclerosis and unstable angina .

HY-150309

PI3K-IN-54	PI3K	Cancer
PI3K-IN-54 (compound 10w) 是一种泛 PI3K 抑制剂。PI3K-IN-54 对 *p110α、p110β、p110δ* 的 IC₅₀ 值分别为 0.22 nM、1.4 nM 和 0.38 nM。PI3K-IN-54 可用于癌症研究。

HY-10108A

LY294002 hydrochloride Maximum Cited Publications 792 Publications Verification	PI3K Casein Kinase DNA-PK Apoptosis	Cancer
LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC₅₀ values of 0.5, 0.57, and 0.97 μM for *P110α, P110δ* and *P110β, respectively. LY294002 hydrochloride also inhibits CK2* with an IC₅₀ of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .

HY-12030

PIK-90 3 Publications Verification	PI3K DNA-PK	Cancer
PIK-90 is a DNA-PK and PI3K inhibitor, which inhibits *p110α, p110γ* and DNA-PK with IC₅₀s of 11, 18 and 13 nM, respectively.

HY-15900

Voxtalisib 5 Publications Verification XL765; SAR245409	PI3K mTOR	Cancer
Voxtalisib (XL765) is a potent PI3K inhibitor, which has a similar activity toward class I PI3K (IC₅₀s=39, 113, 9 and 43 nM for *p110α, p110β, p110γ* and *p110δ, respectively), also inhibits DNA-PK (IC₅₀=150 nM) and mTOR (IC₅₀=157 nM). Voxtalisib (XL765) inhibits mTORC1* and mTORC2 with IC₅₀s of 160 and 910 nM, respectively.

HY-156371

MIPS-21335	PI3K	Cardiovascular Disease
MIPS-21335 is an PI3KC2α inhibitor (IC₅₀: 7 nM). MIPS-21335 also inhibits PI3KC2β, p110α, p110β and p110δ (IC₅₀: 0.043, 0.140, 0.386, 0.742 μM). MIPS-21335 has antithrombotic effect .

HY-50094

Pictilisib 45+ Cited Publications GDC-0941	PI3K Autophagy Apoptosis	Cancer
Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with an IC₅₀ of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

HY-10116

PI-540	PI3K mTOR	Cancer
PI-540 is a bicyclic thienopyrimidine derivative and an orally active PI3K inhibitor. PI-540 has anti-cancer cell proliferation properties and high tissue distribution. PI-540 can inhibit different isoforms of PI3K, with IC₅₀s of 10 nM (P110α), 3510 nM (P110β), 410 nM (P110δ), and 33110 nM (P110γ). PI-540 also inhibits mTOR (IC₅₀: 61 nM) and DNA-PK (IC₅₀: 525 nM) .

HY-20180

Pictilisib dimethanesulfonate 45+ Cited Publications GDC-0941 dimethanesulfonate; GDC-0941 2 MeSO3H salt	PI3K Autophagy Apoptosis	Cancer
Pictilisib dimethanesulfonate (GDC-0941 dimethanesulfonate) is a potent inhibitor of PI3Kα/δ with IC₅₀ of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

HY-12285

Serabelisib MLN1117; INK1117; TAK-117	PI3K	Cancer
Serabelisib (MLN1117) is a selective *p110α* inhibitor with an IC₅₀ of 15 nM.

HY-13261

A66 4 Publications Verification	PI3K	Cancer
A66 is a highly specific and selective *p110α* inhibitor with an IC₅₀ of 32 nM.

HY-13026

Idelalisib 40+ Cited Publications CAL-101; GS-1101	PI3K Autophagy	Cancer
Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable *p110δ* inhibitor with an IC₅₀ of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.

HY-160418

PI3K-IN-51	PI3K	Cancer
PI3K-IN-51 is a PI3K inhibitor with IC₅₀ values <500 nM for p120γ and p110δ/p85α (WO2016204429A1; Example 10) .

HY-N6775

Sonolisib 1 Publications Verification PX-866	PI3K	Cancer
Sonolisib (PX-866), an improved Wortmannin analogue, is an oral, irreversible, and pan-isoform inhibitor of PI3K (IC₅₀=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)). Antitumor activity .

HY-10344

AZD 6482 15+ Cited Publications KIN-193	PI3K Autophagy	Cancer
AZD 6482 (KIN-193) is a potent and selective *p110β* inhibitor with an IC₅₀ of 0.69 nM.

HY-50673A

Dactolisib hydrochloride BEZ235 hydrochloride; NVP-BEZ235 hydrochloride	PI3K mTOR Autophagy	Cancer
Dactolisib (BEZ235) hydrochloride is an orally active, dual pan-class I PI3K and mTOR inhibitor for *p110α*/γ/δ/β and mTOR with IC₅₀ of 4 nM/5 nM/7 nM/75 nM and 20.7 nM, respectively. Dactolisib hydrochloride (BEZ235) inhibits mTORC1 and mTORC2 .

HY-157288

(R)-Phe-A110/B319	Others	Metabolic Disease
(R)-Phe-A110/B319, a hapten, is a selective binder to tumor-associated antigens. (R)-Phe-A110/B319 has a 20-fold higher affinity towards the H1047R mutant of p110α in the p110α/p85α PI3K complex. (R)-Phe-A110/B319 can be used for the research of conditional chimeric antigen receptor T (CAR-T) cell activation and tumor targeting .

HY-111510

IPI-3063	PI3K	Inflammation/Immunology
IPI-3063 is a potent and selective PI3K p110δ inhibitor with an IC₅₀ of 2.5 ± 1.2 nM.

HY-13026S

Idelalisib-d5 CAL-101 d₅; GS-1101 d₅	PI3K Autophagy	Cancer
Idelalisib-d₅ is a deuterium labeled Idelalisib. Idelalisib is a highly selective and orally bioavailable p110δ inhibitor[1].

HY-75124

(Rac)-AZD 6482 (Rac)-KIN-193	PI3K Autophagy	Cancer
(Rac)-AZD 6482 ((Rac)-KIN-193) is the racemate of AZD 6482. AZD 6482 is a potent and selective p110β inhibitor with an IC₅₀ of 0.69 nM.

HY-10297

Omipalisib 15+ Cited Publications GSK2126458; GSK458	PI3K mTOR Autophagy	Cancer
Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of PI3K with K_is of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. Omipalisib has anti-cancer activity .

HY-10114

TGX-221 10+ Cited Publications	PI3K	Cancer
TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit, used for cancer treatment.

HY-123790

AS2541019	PI3K	Inflammation/Immunology
AS2541019 is a PI3Kδ (p110δ) inhibitor. AS2541019 inhibits B cell activation and proliferation, and suppresses xenograft antibody production .

HY-103030

PI3K-IN-32	PI3K	Cancer
PI3K-IN-32 (compound 35) is a potent PI3K p110α inhibitor with an pIC₅₀ of 6.85 .

HY-13228

YM-201636 10+ Cited Publications	PIKfyve PI3K Autophagy Influenza Virus	Infection Cancer
YM-201636 is a potent and selective PIKfyve inhibitor with an IC₅₀ of 33 nM. YM-201636 also inhibits p110α with an IC₅₀ of 3.3 μM. YM-201636 inhibits retroviral replication.

HY-109633A

PI3K-IN-18 dihydrochloride	PI3K	Others
PI3K-IN-18 (Compound 1) dihydrochloride is a 4-morpholino-2-phenylquinazoline derivative and an inhibitor of PI3K p110α .

HY-108606

PI-828 1 Publications Verification	PI3K Casein Kinase	Cancer
PI-828 is a dual PI3K and casein kinase 2 (CK2) inhibitor with IC₅₀s of 173 nM, 149 nM, and 1127 nM for *p110α, CK2, and CK2α2* in lipid kinase assay, respectively .

HY-109198

Zandelisib ME-401; PWT-143	PI3K	Cancer
Zandelisib (ME-401) is a phosphatidylinositol 3-kinase (PI3K) inhibitor extracted from patent WO2019183226 A1, Compound Example 1. Zandelisib selectively inhibits *p110δ* with an IC₅₀ of 3.5 nM. Zandelisib functions as an antineoplastic .

HY-163360

PI3Kα-IN-19	PI3K	Cancer
PI3Kα-IN-19 (Compound 1) is a PI3Kα inhibitor with a targeted binding site at the *p110α* catalytic subunit. PI3Kα is one of the most common dysregulated kinases used in cancer research .

Cat. No.	Product Name

HY-L015

PI3K/Akt/mTOR Compound Library

652 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 652 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P2280

TAT-P110 P110	Dynamin	Neurological Disease Inflammation/Immunology
TAT-P110, a peptide inhibitor of Drp1-Fis1 interaction, reduces pathology in numerous models of neurodegeneration, ischemia, and sepsis without blocking the physiological functions of Drp1 .

HY-P10368

P110 heptapeptide	Dynamin	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
P110 heptapeptide, a peptide inhibitor of Drp1-Fis1 interaction, reduces pathology in numerous models of neurodegeneration, ischemia, and sepsis without blocking the physiological functions of Drp1 .

HY-P6437

Drp1 peptide inhibitor P110	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

Species:	Human (15)
Tag:	His (5) Tag Free (2) Strep (4) Avi (6) GST (3) Flag (1)
Source:	Sf9 insect cells (12) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P703650

	OGT Protein, Human (His) UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit; O-GlcNAc transferase subunit p110; O-linked N-acetylglucosamine transferase 110 kDa subunit (OGT); OGT	Human	E. coli

HY-P701515

	TCEB3 Protein, Human (Sf9) ELOA (TCEB3); Elongin-A; EloA; Elongin 110 kDa subunit; RNA polymerase II transcription factor SIII subunit A1; SIII p110; Transcription elongation factor B polypeptide 3	Human	Sf9 insect cells
	TCEB3, also known as SIII, acts as a key transcription elongation factor that promotes RNA polymerase II progression beyond the blocking site. It interacts with SIII regulatory subunits B and C to form the elongin BC complex, which significantly enhances the transcriptional activity of subunit A. TCEB3 Protein, Human (Sf9) is the recombinant human-derived TCEB3 protein, expressed by Sf9 insect cells , with tag free. The total length of TCEB3 Protein, Human (Sf9) is 797 a.a., .

HY-P701514

	TCEB3 Protein, Human (Sf9, His, StrepⅡ) ELOA (TCEB3); Elongin-A; EloA; Elongin 110 kDa subunit; RNA polymerase II transcription factor SIII subunit A1; SIII p110; Transcription elongation factor B polypeptide 3	Human	Sf9 insect cells
	TCEB3, also known as SIII, acts as a key transcription elongation factor that promotes RNA polymerase II progression beyond the blocking site. It interacts with SIII regulatory subunits B and C to form the elongin BC complex, which significantly enhances the transcriptional activity of subunit A. TCEB3 Protein, Human (Sf9, His, Strep) is the recombinant human-derived TCEB3 protein, expressed by Sf9 insect cells , with N-Strep, N-8*His labeled tag. The total length of TCEB3 Protein, Human (Sf9, His, Strep) is 797 a.a., .

HY-P703467

	*p85/p110* Protein, Human (Active, Sf9, Avi, Biotinylated)** GRB1	Human	Sf9 insect cells

HY-P703466

	*p85/p110* Protein, Human (Active, Sf9, Biotinylated, Avi, H1047R)** GRB1	Human	Sf9 insect cells

HY-P703468

	*p85/p110* Protein, Human (Active, Sf9, Biotinylated, Avi, E542K)** GRB1	Human	Sf9 insect cells
	p85/p110 Protein, Human (Active, Sf9, Biotinylated, Avi, E542K) is the recombinant human-derived p85/p110, expressed by Sf9 insect cells , with Avi labeled tag. ,

HY-P703469

	*p85/p110* Protein, Human (Active, Sf9, Biotinylated, Avi, E545K)** GRB1	Human	Sf9 insect cells
	p85/p110 Protein, Human (Active, Sf9, Biotinylated, Avi, E545K) is the recombinant human-derived p85/p110, expressed by Sf9 insect cells , with Avi labeled tag. ,

HY-P703470

	*p85/p110* Protein, Human (Active, Sf9, Biotinylated, Avi, N345K)** GRB1	Human	Sf9 insect cells
	p85/p110 Protein, Human (Active, Sf9, Biotinylated, Avi, N345K) is the recombinant human-derived p85/p110, expressed by Sf9 insect cells , with Avi labeled tag. ,

HY-P703471

	*p85/p110* Protein, Human (Active, Sf9, Biotinylated, Avi, P539R)** GRB1	Human	Sf9 insect cells
	p85/p110 Protein, Human (Active, Sf9, Biotinylated, Avi, P539R) is the recombinant human-derived p85/p110, expressed by Sf9 insect cells , with Avi labeled tag. ,

HY-P702946

	RB1 Protein, Human (GST) Retinoblastoma-associated protein; p105-Rb; p110-RB1; pRb (Rb); pp110; RB1	Human	E. coli
	RB1 Protein, Human (GST) is the recombinant human-derived RB1, expressed by E. coli , with GST labeled tag. ,

HY-P702894

	*PI3 kinase (p110β/p85α) Protein, Human (sf9, Flag )* PIK3C1; PIK3CB; PIK3R1	Human	Sf9 insect cells
	PI3 kinase (p110β/p85α) Protein, Human (sf9, Flag ) is the recombinant human-derived PI3 kinase (p110β/p85α), expressed by Sf9 insect cells , with the p110β construct contains an N-terminal FLAG-tag whereas p85α has no tag.

HY-P703581

	PK3CD/p85 Protein, Human (Active, Sf9, His, Strep, GST) Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta; PtdIns-3-kinase subunit p110-delta; p110delta; PIK3CD; Homo sapiens; Human; PI3-kinase subunit delta; Kinase; Transferase; 2.7.1.137	Human	Sf9 insect cells
	PK3CD/p85 Protein, Human (Active, Sf9, His, Strep, GST) is the recombinant human-derived PK3CD/p85, expressed by Sf9 insect cells , with Strep, His, GST labeled tag. ,

HY-P703588

	RB1 Protein, Human (StrepⅡ) Retinoblastoma-associated protein; p105-Rb; p110-RB1; pRb; Rb; pp110; RB1; Homo sapiens; Human; Rb; Chromatin regulator; DNA-binding; Repressor	Human	E. coli
	RB1 Protein, Human (Strep) is the recombinant human-derived RB1, expressed by E. coli , with Strep labeled tag. ,

HY-P703582

	PIK3CG Protein, Human (Sf9, His, GST) Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma; PtdIns-3-kinase subunit p110-gamma; p110gamma; Phosphoinositide-3-kinase catalytic gamma polypeptide; Serine/threonine protein kinase PIK3CG; 2.7.11.1; p120-PI3K; PIK3CG; Homo sapiens; Human; PI3-kinase subunit gamma; Kinase; Serine/threonine-protein kinase; Transferase; 2.7.1.137	Human	Sf9 insect cells
	PIK3CG Protein, Human (Sf9, His, GST) is the recombinant human-derived PIK3CG, expressed by Sf9 insect cells , with His, GST labeled tag. ,

HY-P703580

	PIK3CA Protein, Human (Active, Sf9, His, StrepⅡ) Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; PtdIns-3-kinase subunit p110-alpha; p110alpha; Phosphoinositide 3-kinase alpha; Phosphoinositide-3-kinase catalytic alpha polypeptide; Serine/threonine protein kinase PIK3CA; 2.7.11.1; PIK3CA; Homo sapiens; Human; PI3-kinase subunit alpha; Kinase; Serine/threonine-protein kinase; Transferase; 2.7.1.137	Human	Sf9 insect cells
	PIK3CA Protein, Human (Active, Sf9, His, Strep) is the recombinant human-derived PIK3CA, expressed by Sf9 insect cells , with Strep, His labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81162

	*PI3 Kinase p110* alpha/PIK3CA Antibody** PI3 kinase p110 subunit alpha; caPI3K; MGC142161; MGC142163; p110 alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI3 kinase p110 subunit alpha; PI3K; PI3KC A; PIK3C A; PK3CA; PtdIns 3 kinase p110; PI3-kinase P110α; PI3-kinase p110 subunit alpha; PI 3 Kinase catalytic subunit alpha; PK3CA_HUMAN; PI3 kinase P110α.	WB, ICC/IF, IP	Human, Mouse, Rat
	PIK3CA Antibody is an unconjugated, approximately 110 kDa, rabbit-derived, anti-PIK3CA monoclonal antibody. PIK3CA Antibody can be used for: WB, ICC/IF, IP expriments in human, mouse, rat background without labeling.

HY-P80865

	*PI3 Kinase p110* gamma Antibody (YA690)** 1 Publications Verification PI3K; PIK3; PI3CG; PI3Kgamma; p110gamma; p120-PI3K	WB	Human
	PI3 Kinase p110 gamma Antibody (YA690) is a non-conjugated and Mouse origined monoclonal antibody about 126 kDa, targeting to PI3 Kinase p110 gamma (2D10). It can be used for WB assays with tag free, in the background of Human.

HY-P81211

	*phospho-PI3 Kinase p110* beta (Ser1070) Antibody** 1 Publications Verification PI3-kinase p110 subunit beta; p-PI3Kβ(Ser1070); PI 3-kinase C2β; p110 BETA; p110Beta; Phosphatidylinositol 3 kinase catalytic beta polypeptide; Phosphatidylinositol 4 5 bisphosphate 3 kinase 110 kDa catalytic subunit beta; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit beta isoform; Phosphatidylinositol-4; Phosphoinositide 3 kinase catalytic beta polypeptide; PI3 kinase p110 subunit beta; PI3-kinase subunit beta; PI3K; PI3K beta; PI3K-beta; PI3Kbeta; PI3KCB; PIK3C1; Pik3cb; PK3CB_HUMAN; PtdIns 3 kinase p110; PtdIns-3-kinase subunit beta; PtdIns-3-kinase subunit p110-beta; 5-bisphosphate 3-kinase 110 kDa catalytic subunit beta; 5-bisphosphate 3-kinase catalytic subunit beta isoform.	WB, ELISA, IHC-P, IHC-F, ICC/IF	Human, Mouse, Rat
	phospho-PI3 Kinase p110 beta (Ser1070) Antibody is an unconjugated, approximately 110-123 kDa, rabbit-derived, anti-phospho-PI3 Kinase p110 beta (Ser1070) polyclonal antibody. phospho-PI3 Kinase p110 beta (Ser1070) Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, and predicted: chicken, dog, pig, cow, horse, guinea pig background without labeling.

HY-P83439

	Protein CASP Antibody (YA3184) CDP; CUX; p75; CASP; CDP1; COY1; Clox; GDDI; p100; p110; p200; CUTL1; GOLIM6; CDP/Cut; Cux/CDP; Nbla10317	WB, ICC/IF, IP	Human, Mouse, Rat
	Protein CASP Antibody (YA3184) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3184), targeting Protein CASP, with a predicted molecular weight of 77 kDa (observed band size: 77 kDa). Protein CASP Antibody (YA3184) can be used for WB, ICC/IF, IP experiment in human, mouse, rat background.

HY-P81872

	*PI3 Kinase p110* delta Antibody (YA1617)** PIK3CD; Phosphatidylinositol 4; 5-bisphosphate 3-kinase catalytic subunit delta isoform; PI3-kinase subunit delta; PI3K-delta; PI3Kdelta; PtdIns-3-kinase subunit delta; Phosphatidylinositol 4; 5-bisphosphate 3-kinase 110 kDa catalytic subunit delta; PtdIns-3-kinase subunit p110-delta; p110delta	WB, ICC/IF	Human, Mouse, Rat
	PI3 Kinase p110 delta Antibody (YA1617) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1617), targeting PI3 Kinase p110 delta, with a predicted molecular weight of 119 kDa (observed band size: 119 kDa). PI3 Kinase p110 delta Antibody (YA1617) can be used for WB, ICC/IF experiment in human, mouse, rat background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: